
    
      OBJECTIVE: To compare the performance of raloxifene and strontium rannelate in the management
      of women with postmenopausal osteoporosis.

      DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS:
      80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or
      strontium ranelate (2g/d). Participants were followed for 1 year.

      MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of
      efficacy, including changes in bone mineral density and bone biochemical markers.
    
  